IQVIA Holdings Inc. (IQV) company profile
Close on Nov 17, 2026Market cap $42.45BP/E 31.3Yield –
About Iqvia
Services-Commercial Physical & Biological Research, SIC 8731
IQVIA provides clinical research services, healthcare intelligence, and commercial solutions to the life sciences and healthcare sectors. The company operates primarily through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Its portfolio includes cloud-based software platforms, real-world evidence analytics, strategic consulting, end-to-end clinical trial management, laboratory services, and stakeholder engagement programs. IQVIA serves biotechnology, pharmaceutical, medical device, and consumer health companies, as well as healthcare providers, payers, government bodies, researchers, and pharmacies.
The company operates globally with approximately 93,000 employees across more than 100 countries. It serves over 10,000 clients worldwide, maintaining clinical research networks across nearly 50 locations and conducting healthcare professional and product tracking in dozens of international markets. The provided text does not state the company's headquarters location.
Summary of the business section of Iqvia's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IQVIA Holdings Inc.
- Founded
- 2016
- Headquarters
- Durham, NC
- Address
- 2400 Ellis Road 27703
- Phone
- (919) 998-2000
- Website
- iqvia.com
- Employees
- 93,000, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- IQV
- Former tickers
- Q until Feb 16, 2018
- Exchange
- NYSE
- IPO date
- May 9, 2013
- Shares outstanding
- 165M, Oct 20, 2026
- Public float
- $26.50B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1478242
- CUSIP
- 46266C105
- ISIN
- US46266C1053
- FIGI
- BBG00333FYS2
- Share class FIGI
- BBG00333FZ54
- LEI
- 549300W3R20NM4KQPH86
- EIN
- 27-1341991
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ari Bousbib | See Remarks, Director | 1,526,400 |
| Eric Sherbet | See Remarks | 20,999 |
| James G. Berkshire | See Remarks | 13,558 |
| W. Richard Staub | See Remarks | 13,312 |
| Bhavik Patel | See Remarks | 1,348 |
| Keriann Cherofsky | See Remarks | 2,989 |
| Michael J. Fedock | See Remarks | 9,472 |
| Bernd Haas | See Remarks | 24,394 |
| Alistair Grenfell | See Remarks | 29,669 |
| Ronald E. Bruehlman | See Remarks | 55,996 |
| John G. Danhakl | Director | 34,857 |
| Morris Leslie Wims | Director | 2,058 |
| Colleen A. Goggins | Director | 14,453 |
| Jim Fasano | Director | 1,063 |
| John M. Leonard | Director | 16,946 |
| William G. Kaelin Jr | Director | – |
| Carol Burt | Director | 7,533 |
| Sheila A. Stamps | Director | 2,058 |
| John Connaughton | Director | 1,047 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $28.13M | $36.07M | $8.87M | $126 | $187 |
| FY2024 | $26.73M | $11.45M | $6.58M | $110 | $159 |
| FY2023 | $29.15M | $42.29M | $4.52M | $129 | $148 |
| FY2022 | $30.14M | $5.96M | $5.01M | $114 | $138 |
| FY2021 | $28.62M | $88.42M | $4.40M | $157 | $136 |
| FY2020 | $25.58M | $44.63M | $2.89M | $116 | $115 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Ari Bousbib Chairman and Chief Executive Officer | $1.80M | $15.75M | $4.53M | $4.97M | $1.08M | $28.13M | +5% |
| Ronald E. Bruehlman Executive Vice President, Chief Financial Officer | $905.00K | $6.75M | $2.25M | $1.29M | $244.83K | $11.44M | +37% |
| W. Richard Staub, III President, Research & Development Solutions | $800.00K | $5.25M | $1.75M | $943.01K | $86.07K | $8.83M | -18% |
| Alistair R. Grenfell President, Commercial Solutions | $629.91K | $6.00M | $2.00M | $806.95K | $267.74K | $9.70M | – |
| Eric M. Sherbet Executive Vice President, General Counsel and Secretary | $665.00K | $3.00M | $999.95K | $764.30K | $71.57K | $5.50M | +32% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 9, 2013
- Securities offered
- 23,684,210
- Exchange
- NYSE
- First trading day
- May 9, 2013
- First-day close
- $42.11
- Lock-up ends (est.)
- Nov 5, 2013
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 5, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Nov 3, 2017 | Name change | Name changed from Quintiles IMS Holdings, Inc. to IQVIA Holdings Inc. |
| Oct 3, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 22, 2016 | Name change | Name changed from Quintiles Transnational Holdings Inc. to Quintiles IMS Holdings, Inc. |
| Jun 3, 2016 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 9, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| May 2, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?